SCHEMBL6910965

SCHEMBL6910965

Nc1nn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2O)c2nc[nH]c(=O)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 9/20 0.58
DOT1L Q8TEK3 1/20 0.58
DCLK1 O15075 1/20 0.58
DAPK3 O43293 1/20 0.58
DYRK3 O43781 1/20 0.58
CDK1 P06493 1/20 0.58
ROS1 P08922 1/20 0.58
RPS6KB1 P23443 1/20 0.58
CDK2 P24941 1/20 0.58
FLT3 P36888 1/20 0.58
CSNK1A1 P48729 1/20 0.58
CSNK1D P48730 1/20 0.58
CLK2 P49760 1/20 0.58
IRAK1 P51617 1/20 0.58
CDK5 Q00535 1/20 0.58
DYRK1A Q13627 1/20 0.58
MELK Q14680 1/20 0.58
NTRK3 Q16288 1/20 0.58
HIPK4 Q8NE63 1/20 0.58
SLK Q9H2G2 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6910971 1.00 ADK (0.58) ADKDOT1LDCLK1DAPK3DYRK3
SCHEMBL6910977 0.88 ADK (0.65) ADKDOT1LDCLK1DAPK3DYRK3
SCHEMBL6910983 0.88 ADK (0.65) ADKDOT1LDCLK1DAPK3DYRK3
Hydrochloric Acid SCHEMBL31238488 0.88 ADK (0.52) ADKDOT1LDCLK1DAPK3DYRK3
SCHEMBL3490107 0.88 ATG7 (0.52) ADKDOT1LDCLK1DAPK3DYRK3
SCHEMBL3211889 0.86 ADK (0.49) ADKDOT1LDCLK1DAPK3DYRK3
SCHEMBL6912039 0.79 ALDH1A1 (0.55) ADKDOT1LSMN1; SMN2LMNAALDH1A1
SCHEMBL1144829 0.79 ALDH1A1 (0.55) ADKDOT1LSMN1; SMN2LMNAALDH1A1
SCHEMBL6912032 0.79 ALDH1A1 (0.55) ADKDOT1LSMN1; SMN2LMNAALDH1A1
SCHEMBL7213421 0.77 ALDH1A1 (0.57) ADKDOT1LSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0961775-B1 PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS (US) 2004-07-14 EP disclosed
US-6479463-B1 USED TO TREAT AN INFECTION, AN INFESTATION, A NEOPLASM, OR AN AUTOIMMUNE DISEASE OR TO MODULATE ASPECTS OF THE IMMUNE SYSTEM, INCLUDING MODULATION OF TH1 AND TH2 ICN PHARMACEUTICALS, INC. 2002-11-12 US disclosed
US-20020058635-A1 Purine L-nucleosides, analogs and uses thereof AVERETT DEVRON R (US) 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058635-A1 Purine L-nucleosides, analogs and uses thereof PNP, NUDT1, TYMP ADK 80/4885DOT1L 2604/4885DCLK1 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.